COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02722304




Registration number
NCT02722304
Ethics application status
Date submitted
23/03/2016
Date registered
30/03/2016
Date last updated
9/12/2019

Titles & IDs
Public title
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
Scientific title
A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)
Secondary ID [1] 0 0
460503
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 0 0
Alpha1-antitrypsin Deficiency 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - ARALAST NP 60 mg/kg
Other interventions - ARALAST NP 120 mg/kg
Other interventions - GLASSIA 60 mg/kg
Other interventions - GLASSIA 120 mg/kg
Other interventions - Human Albumin 2%

Experimental: ARALAST NP 60 mg/kg - 60 mg/kg body weight/week

Experimental: ARALAST NP 120 mg/kg - 120 mg/kg body weight/week

Experimental: GLASSIA 60 mg/kg - 60 mg/kg body weight/week

Experimental: GLASSIA 120 mg/kg - 120 mg/kg body weight/week

Placebo Comparator: Placebo - Human Albumin 2%


Other interventions: ARALAST NP 60 mg/kg
ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Other interventions: ARALAST NP 120 mg/kg
ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Other interventions: GLASSIA 60 mg/kg
GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Other interventions: GLASSIA 120 mg/kg
GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

Other interventions: Human Albumin 2%
Human albumin 2% (by appropriate dilution with normal saline solution)

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Rate of Change in Lung Density Based on Group 1 (ARALAST NP) Versus Placebo, Group 3 and Group 4 (GLASSIA) Versus Placebo - Rate of change in lung density was assessed by computed tomography (CT) densitometry. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. CT lung density at the 15th percentile (PD15) is the threshold below which 15% of the voxels have lower densities, and was used as the parameter for estimating the rate of lung density decline. Rate of change in lung density based on Group 1 (ARALAST NP) versus Placebo, Group 3 and Group 4 (GLASSIA) versus Placebo were reported. The safety analysis set used for all the efficacy parameter assessment.
Timepoint [1] 0 0
Baseline, Early termination of the study (approximately 22 months)
Secondary outcome [1] 0 0
Rate of Change in Lung Density for Each Treatment Group - Rate of change in lung density was assessed by computed tomography (CT) densitometry for each treatment group. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. The safety analysis set used for all the efficacy parameter assessment.
Timepoint [1] 0 0
Baseline, Early termination of the study (approximately 22 months)
Secondary outcome [2] 0 0
Mean Steady State Trough Concentration of Antigenic and Functional Alpha1-Proteinase Inhibitor (A1PI) for ARALAST NP and GLASSIA at Each Dose Level - Mean steady state trough concentration of antigenic and functional alpha1-proteinase inhibitor (a1pi) for ARALAST NP and GLASSIA at each dose level was reported.
Timepoint [2] 0 0
Baseline, Early termination of the study (approximately 22 months)
Secondary outcome [3] 0 0
Number of Events With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Event (TEAE) - An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. TEAE related to Investigational Product (IP) and Study Procedures (SP) were considered. A non-serious AE is an AE that does not meet the criteria of an SAE. Number of events with related and unrelated serious and non-serious TEAE were reported.
Timepoint [3] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [4] 0 0
Percentage of Participants With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Events (TEAE's) - An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAE related to IP and Study Procedures were considered. Percentage of participants with related and unrelated serious and non-serious TEAE were reported.
Timepoint [4] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [5] 0 0
Number of Events With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs) - An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.
Timepoint [5] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [6] 0 0
Percentage of Participants With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs) - An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.
Timepoint [6] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [7] 0 0
Number of Events With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs) - An Adverse Reactions (ARs) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.
Timepoint [7] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [8] 0 0
Percentage of Participants With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs) - An Adverse Reactions (AR) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.
Timepoint [8] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [9] 0 0
Percentage of Participants With at Least One Infusion Rate Change or Infusion Interruption or Stopped Due to AEs - An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Number of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to adverse events (AEs) were reported.
Timepoint [9] 0 0
From start of study treatment up to early termination of the study (approximately 22 months)
Secondary outcome [10] 0 0
Number of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA - Number of participants who developed anti- A1PI antibodies following treatment with ARALAST NP or GLASSIA were reported. Anti-A1PI binding antibody were determined for the samples that tested positive or negative at each assessment time point.
Timepoint [10] 0 0
Baseline, Early termination of the study (approximately 22 months)

Eligibility
Key inclusion criteria
1. =18 years of age at the time of screening

2. Endogenous plasma Alpha1-Proteinase Inhibitor (A1PI) level <8 µM at any time during
the Screening period for treatment-naïve participants, or following 4-weeks minimum
wash-out from previous augmentation therapy in treatment-experienced participants. The
screening plasma A1PI level may be repeated if a participant obtains an exclusionary
value that is suspected to be due to inadequate washout of A1PI).

3. Participant has documented A1PI genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z,
Pi*Null/Null, or other rare genotypes (except PI*MS, PI*MZ, or PI*SZ).

4. Clinically evident mild-moderate chronic obstructive pulmonary disease (COPD)
(according to GOLD criteria for diagnosis) at the time of screening.

5. If the participant is treated with any respiratory medications including inhaled
bronchodilators, inhaled corticosteroids, or systemic corticosteroids (e.g. prednisone
= 10 mg/day or its equivalent), the doses of the participant's medications have
remained stable for at least 28 days prior to screening.

6. No clinically significant abnormalities (other than emphysema, bronchitis or
bronchiectasis) detected via a chest computed tomography (CT) or chest X-ray at the
time of screening.

7. If female of childbearing potential, participant must have a negative pregnancy test
at screening and agree to employ adequate birth control measures for the duration of
the study.

8. Participant is willing and able to comply with the requirements of the protocol.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known ongoing or history of clinically significant pulmonary impairment other than
emphysema/ COPD.

2. The participant is experiencing lower respiratory infection (LRTI)/acute pulmonary
exacerbation (APE) at the time of enrollment (signing Informed consent form (ICF)).
Participant may be rescreened after both clinical resolution of LRTI/APE and having
also remained stable for at least 4 weeks after the end of LRTI/APE).

3. Known ongoing or history of cor pulmonale.

4. Known resting partial pressure of carbon dioxide (PaCO2) levels of > 45 mmHg.

5. Clinically significant congestive heart failure with New York Heart Association (NYHA)
Class III/IV symptoms.

6. The participant has received an organ transplant, has undergone major lung surgery, or
is currently on a transplant list.

7. Known history of ongoing malignancy (other than adequately treated basal cell or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix).

8. Smoker or participant that has ceased smoking for less than one year prior to
screening whose levels of cotinine are outside of the normal range of a nonsmoker.

All participants must agree to refrain from smoking throughout the course of the
study.

9. The participant is receiving long-term therapy (> 28 days) of parenteral
corticosteroids or oral corticosteroids at doses greater than 10 mg/day of prednisone
or its equivalent).

10. The participant is receiving long-term round-the-clock oxygen supplementation (other
than temporary for acute COPD exacerbation, or supplemental oxygen (O2) with
continuous positive airway pressure [CPAP], or bi-level positive airway pressure
[BiPAP] during the day).

11. Participant has contraindications for CT (e.g. body weight and/or body size exceeding
the weight and gantry size limits specified by the manufacturer of the CT scanner,
inability to lie flat in the CT scanner, claustrophobia, metal prosthesis or pacemaker
in the chest wall or upper extremity that would impact lung density assessment).

12. Participant is unwilling or unable to modify bronchodilator medications for 6 hours
for short acting ß2 agonists, 24 hours for long-acting ß2 agonists, and 48 hours for
long acting anticholinergics prior to the scheduled quantitative CT scan.

13. Known severe immunoglobulin A (IgA) deficiency (ie, IgA level < 8 mg/dL at screening).

14. Known history of hypersensitivity following infusions of human blood or blood
components (eg, human immunoglobulins or human albumin).

15. Presence of clinically significant laboratory abnormalities at the screening

16. The participant has a clinically significant medical, psychiatric, or cognitive
illness, is a recreational drug/alcohol user, or has any other uncontrolled medical
condition (eg, unstable angina, transient ischemic attack, uncontrolled hypertension)
that, in the opinion of the investigator, would affect participant's safety or
compliance or confound the results of the study.

17. Participant has been exposed to another IP within 28 days prior to enrollment or is
scheduled to participate in another clinical study involving an IP or investigational
device during the course of this study.

18. Participant is a family member or employee of the investigator.

19. If female, participant is pregnant or nursing at the time of enrollment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment postcode(s) [1] 0 0
34741 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Canada
State/province [9] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Baxalta now part of Shire
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Baxalta Innovations GmbH, now part of Shire
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of
weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects
with A1PI deficiency and emphysema/ chronic obstructive pulmonary disease (COPD).
Trial website
https://clinicaltrials.gov/show/NCT02722304
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Shire
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02722304